cranium-2099083_640

Study shows that drug slows brain shrinkage in multiple sclerosis

September 12, 2018 | Southmedia

Source UAB News: Results from a clinical trial of more than 250 participants with progressive multiple sclerosis revealed that ibudilast was better than a placebo in slowing down brain shrinkage. 

The study also showed that the main side effects of ibudilast were gastrointestinal and headaches. The study was supported by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, and was published in the New England Journal of Medicine.

Robert J. Fox, M.D., a neurologist at Cleveland Clinic in Ohio, led a team of researchers across 28 clinical sites, including a team from the University of Alabama at Birmingham, in a brain imaging study to investigate whether ibudilast was better than placebo in reducing the progression of brain atrophy, or shrinkage, in patients with progressive multiple sclerosis.  Read on.

 

Scroll to Top
Skip to content